MX2023002545A - Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. - Google Patents
Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.Info
- Publication number
- MX2023002545A MX2023002545A MX2023002545A MX2023002545A MX2023002545A MX 2023002545 A MX2023002545 A MX 2023002545A MX 2023002545 A MX2023002545 A MX 2023002545A MX 2023002545 A MX2023002545 A MX 2023002545A MX 2023002545 A MX2023002545 A MX 2023002545A
- Authority
- MX
- Mexico
- Prior art keywords
- cell lymphoma
- bispecific antibody
- diffuse large
- combination therapy
- antibody against
- Prior art date
Links
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 title abstract 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Se proporcionan métodos de tratamiento clínico del linfoma difuso de células B grandes (DLBCL) (por ejemplo, DLBCL de alto riesgo no tratado previamente) en sujetos humanos usando un anticuerpo biespecífico que se une a CD3 y CD20 en combinación con el régimen de cuidado estándar de R-CHOP (rituximab, ciclofosfamida, doxorrubicina, vincristina y prednisona).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063076797P | 2020-09-10 | 2020-09-10 | |
PCT/EP2021/075016 WO2022053654A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002545A true MX2023002545A (es) | 2023-03-14 |
Family
ID=77924348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002545A MX2023002545A (es) | 2020-09-10 | 2021-09-10 | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20240034812A1 (es) |
EP (1) | EP4210747A1 (es) |
JP (1) | JP2023541860A (es) |
KR (1) | KR20230066583A (es) |
CN (1) | CN116472058A (es) |
AU (1) | AU2021340232A1 (es) |
BR (1) | BR112023004321A2 (es) |
CA (1) | CA3192251A1 (es) |
IL (1) | IL301085A (es) |
MX (1) | MX2023002545A (es) |
WO (1) | WO2022053654A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021339006A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma |
JP2023542289A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー/エス | 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
IL301098A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma |
WO2023144306A1 (en) * | 2022-01-28 | 2023-08-03 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
WO2024006925A2 (en) * | 2022-07-01 | 2024-01-04 | Nkarta, Inc. | Dosing regimens for cd19-directed cancer immunotherapy |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
ATE276199T1 (de) | 1999-02-03 | 2004-10-15 | Biosante Pharmaceuticals Inc | Methoden zur herstellung von therapeutische kalzium-phosphat partikeln |
WO2004009618A2 (en) | 2002-07-18 | 2004-01-29 | Crucell Holland B.V. | Recombinant production of mixtures of antibodies |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP5686953B2 (ja) | 2005-10-11 | 2015-03-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用 |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
CN101802015B (zh) | 2007-03-29 | 2015-05-06 | 根马布股份公司 | 双特异性抗体及其制造方法 |
EP2068923A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES |
ES2695047T3 (es) | 2007-04-03 | 2018-12-28 | Amgen Research (Munich) Gmbh | Dominio de unión específico entre especies |
EP2155790A1 (en) | 2007-05-31 | 2010-02-24 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
CN107226864A (zh) | 2007-06-21 | 2017-10-03 | 宏观基因有限公司 | 共价双抗体及其用途 |
ES2622460T3 (es) | 2007-09-26 | 2017-07-06 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
MX350962B (es) | 2008-01-07 | 2017-09-27 | Amgen Inc | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. |
JP2009212059A (ja) | 2008-03-06 | 2009-09-17 | Toshiba Corp | 電動軽車両のバッテリ装置 |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
KR20110104032A (ko) | 2008-12-19 | 2011-09-21 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이의 용도 |
KR20110134494A (ko) | 2009-03-27 | 2011-12-14 | 자이모제네틱스, 인코포레이티드 | 항체-수용체 조합물을 포함하는 다중특이적-결합 단백질을 사용하기 위한 조성물 및 방법 |
CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AU2010324684B2 (en) | 2009-11-30 | 2015-09-03 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
RU2016105962A (ru) | 2009-12-04 | 2018-11-23 | Дженентек, Инк. | Мультиспецифические антитела, аналоги антител, композиции и способы |
WO2011090762A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
SG10201800757TA (en) | 2010-04-20 | 2018-02-27 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
CA2807269A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
MX352929B (es) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc. |
KR102244173B1 (ko) | 2010-11-30 | 2021-04-26 | 추가이 세이야쿠 가부시키가이샤 | 세포상해 유도 치료제 |
CN103796677B (zh) | 2011-04-20 | 2019-08-16 | 健玛保 | 针对her2和cd3的双特异性抗体 |
PL2714733T4 (pl) | 2011-05-21 | 2019-08-30 | Macrogenics, Inc. | Cząsteczki wiążące CD3 zdolne do wiązania z ludzkim i nieludzkim CD3 |
CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
UA116192C2 (uk) | 2011-08-23 | 2018-02-26 | Рош Глікарт Аг | Активуюча т-клітини біоспецифічна антигензв'язуюча молекула |
AU2012328322A1 (en) | 2011-10-27 | 2014-06-12 | Genmab A/S | Production of heterodimeric proteins |
CN104271122A (zh) | 2012-02-16 | 2015-01-07 | 桑塔鲁斯股份有限公司 | 抗vla1(cd49a)抗体药物组合物 |
LT2838918T (lt) | 2012-04-20 | 2019-09-10 | Merus N.V. | Būdai ir priemonės heterodimerinių ig-tipo molekulių gamybai |
PT2869845T (pt) | 2012-07-06 | 2019-12-09 | Genmab Bv | Proteína dimérica com mutações triplas |
AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
KR101569083B1 (ko) | 2012-11-21 | 2015-11-16 | 주식회사 파멥신 | Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물 |
KR20150122203A (ko) | 2013-02-26 | 2015-10-30 | 로슈 글리카트 아게 | T 세포 활성화 이중특이적 항원 결합 분자 |
RU2015140915A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
WO2015001085A1 (en) | 2013-07-05 | 2015-01-08 | Genmab B.V. | Humanized or chimeric cd3 antibodies |
CA2917886A1 (en) | 2013-07-12 | 2015-01-15 | Zymeworks Inc. | Bispecific cd3 and cd19 antigen binding constructs |
PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
TW201542226A (zh) | 2014-02-12 | 2015-11-16 | Sanofi Sa | 抗-il-4/抗-il-13雙特異性抗體/聚麩胺酸配製物 |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
MX2017006312A (es) | 2014-11-17 | 2017-08-21 | Regeneron Pharma | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. |
CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
US20160199399A1 (en) | 2015-01-09 | 2016-07-14 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness in cancer patients |
CN104922688A (zh) | 2015-02-10 | 2015-09-23 | 昆明贵研药业有限公司 | 奥沙利铂的环糊精复合物及制备方法 |
US11359015B2 (en) | 2015-07-15 | 2022-06-14 | Genmab A/S | Humanized or chimeric CD3 antibodies |
EP3464370A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
ES2888298T3 (es) | 2017-04-27 | 2022-01-03 | Astrazeneca Ab | Compuestos de C5-anilinoquinazolina y su uso en el tratamiento de cáncer |
EP3749360A1 (en) | 2018-02-09 | 2020-12-16 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
BR112022002653A2 (pt) | 2019-08-15 | 2022-05-03 | Genmab As | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit de partes |
US20210371538A1 (en) | 2020-05-08 | 2021-12-02 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
AU2021342343A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
IL301098A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma |
AU2021339006A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma |
JP2023542289A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー/エス | 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
-
2021
- 2021-09-10 KR KR1020237011631A patent/KR20230066583A/ko unknown
- 2021-09-10 EP EP21777974.3A patent/EP4210747A1/en active Pending
- 2021-09-10 IL IL301085A patent/IL301085A/en unknown
- 2021-09-10 US US18/025,203 patent/US20240034812A1/en active Pending
- 2021-09-10 MX MX2023002545A patent/MX2023002545A/es unknown
- 2021-09-10 JP JP2023515674A patent/JP2023541860A/ja active Pending
- 2021-09-10 WO PCT/EP2021/075016 patent/WO2022053654A1/en active Application Filing
- 2021-09-10 CA CA3192251A patent/CA3192251A1/en active Pending
- 2021-09-10 CN CN202180070059.6A patent/CN116472058A/zh active Pending
- 2021-09-10 AU AU2021340232A patent/AU2021340232A1/en active Pending
- 2021-09-10 BR BR112023004321A patent/BR112023004321A2/pt unknown
- 2021-12-21 US US17/558,430 patent/US11845805B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2023541860A (ja) | 2023-10-04 |
EP4210747A1 (en) | 2023-07-19 |
US11845805B2 (en) | 2023-12-19 |
CA3192251A1 (en) | 2022-03-17 |
WO2022053654A1 (en) | 2022-03-17 |
US20240034812A1 (en) | 2024-02-01 |
AU2021340232A1 (en) | 2023-04-13 |
KR20230066583A (ko) | 2023-05-16 |
CN116472058A (zh) | 2023-07-21 |
IL301085A (en) | 2023-05-01 |
US20220119544A1 (en) | 2022-04-21 |
BR112023004321A2 (pt) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002545A (es) | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. | |
MX2023002540A (es) | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular. | |
MX2023002544A (es) | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para tratar linfoma folicular. | |
MX2023002542A (es) | Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. | |
MX2023002541A (es) | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. | |
MX2022013797A (es) | Anticuerpos biespecificos contra cd3 y cd20. | |
Younes et al. | Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma | |
Chong et al. | Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
MX2023002546A (es) | Anticuerpos biespecificos contra cumulo de diferenciacion 3 (cd3) y contra cumulo de diferenciacion 20 (cd20) para tratar leucemia linfocitica cronica. | |
CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
Annede et al. | Radiobiology: Foundation and new insights in modeling brachytherapy effects | |
CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
D’Auria et al. | Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia | |
Dewan et al. | Oxidative stress in cerebrospinal fluid during treatment in childhood acute lymphoblastic leukemia | |
Tanaka et al. | High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing’s tumors | |
Johnson et al. | Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas. | |
RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
Boudreaux et al. | Primary cutaneous epidermotropic marginal zone B-cell lymphoma treated with total skin electron beam therapy | |
Mian et al. | Sequential loss of B‐cell target antigens in multiply relapsed high‐grade B‐cell lymphoma treated with targeted therapies | |
MX2022005400A (es) | Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos. | |
To et al. | Effect of lethal total body irradiation on bone marrow chimerism, acute graft-versus-host disease, and tumor engraftment in mouse models: impact of different radiation techniques using low-and high-energy X-rays | |
Mazraani et al. | A Rare Presentation of Collision Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Treated with R-CHOP and Adjuvant Radiation Therapy | |
Moshfeghi et al. | Therapeutic effects of fludarabine-cyclophosphamide combined therapy in Iranian patients with B-cell chronic lymphocytic leukemia. | |
Jurczak et al. | The use of Yttrium-90 Ibritumomab Tiuxetan (90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation |